Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| The Interuniversity Cardiology Institute of the Netherlands | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether NT-proBNP guided treatment of chronic congestive heart failure will reduce heart failure related morbidity and mortality compared to therapy guided by standard clinical judgement.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| NT-proBNP guided treatment group | Active Comparator | In this group, management was guided by an individually set NT-proBNP, defined by the lowest level at discharge or 2 weeks thereafter. If NT-proBNP levels were elevated above the individually set NT-proBNP interventions were performed according to the ESC heart failure guidelines. |
|
| Clinically guided arm | Placebo Comparator | Heart failure treatment guided by clinical assessment. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| NT-proBNP measurements | Device |
|
| Measure | Description | Time Frame |
|---|---|---|
| Difference in total number of days alive and outside the hospital between the NT-proBNP guided and the clinical guided group. | minimum of one year |
| Measure | Description | Time Frame |
|---|---|---|
| All cause mortality | at least one year | |
| Cardiovascular mortality | at least one year | |
| All cause hospitalization |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Dave JW van Kraaij, MD | Maastricht University Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Universtiy Hospital Maastricht | Maastricht | Limburg | 5800 | Netherlands |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 21144969 | Derived | Eurlings LW, van Pol PE, Kok WE, van Wijk S, Lodewijks-van der Bolt C, Balk AH, Lok DJ, Crijns HJ, van Kraaij DJ, de Jonge N, Meeder JG, Prins M, Pinto YM. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol. 2010 Dec 14;56(25):2090-100. doi: 10.1016/j.jacc.2010.07.030. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| at least one year |
| Cardiovascular related hospitalization | at least one year |
| Total number of hospitalizations and mortality | at least one year |
| Total number of cardiovascular hospitalizations and mortality | at least one year |
| Differences in primary and secondary outcome measures among renal function and age subgroups | At least one year |
| Differences in evidence based heart failure medication prescription after 3, 6 and 12 months | At least one year |
| Analysis of major endpoints in patients where NT-proBNP levels were at or below the individual target level in at least 75% of all outpatient visits | at least one year |